Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004982 · ClinicalTrials.gov registry record · Phase 1
Combination Iron Chelation Therapy
A Phase 1 study of Thalassemia and Iron Overload, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00004982 is a Phase 1 study of Thalassemia and Iron Overload that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The trial reports 1 study location across 1 state.
The verdict
NCT00004982, a Phase 1 study of Thalassemia and Iron Overload, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
Patients with beta-thalassemia (Cooley's Anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy. Compliance with the use of the only FDA-approved drug for removing excess iron from patients (Desferal) continues to be a major problem despite convincing evidence that it markedly reduces morbidity and prolongs life. The full potential of iron-chelation therapy will not be realized until an orally-effective drug is available. This small trial is testing the premise that a combination of drugs as a new approach to iron chelation therapy may reduce side effects and increase efficacy. If both drugs can be given orally, there may be a better chance of finding a suitable alternative to Desferal. Several combinations of experimental iron chelating drugs are being used in this trial.
Conditions Studied
Interventions
- DRUG Combination Iron Chelation Therapy
Study Locations (1)
New York
- Cornell University Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-12 |
| Est. Completion | 2002-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004982
The ClinicalTrials.gov registry entry for NCT00004982 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Thalassemia appearing as the primary indexed condition, and to 1 intervention - of which Combination Iron Chelation Therapy is the first listed.
NCT00004982 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00004982 about?
NCT00004982 is a clinical study titled "Combination Iron Chelation Therapy". Patients with beta-thalassemia (Cooley's Anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy. Compliance with the use of the only FDA-approved drug for removing excess iron from patients (Desferal) continues to be a major pr...
What is the current status of trial NCT00004982?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-12. Estimated completion is 2002-11.
What conditions does trial NCT00004982 study?
This clinical trial studies the following conditions: Thalassemia, Iron Overload.
What interventions are being tested in trial NCT00004982?
The interventions under investigation include: Combination Iron Chelation Therapy (DRUG).
Who is sponsoring clinical trial NCT00004982?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004982 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thalassemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Blood Stem Cell Transplant for Sickle Cell Disease
ACTIVE NOT RECRUITING · Phase 1
-
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
COMPLETED · Phase 1
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
RECRUITING · Phase 3
-
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
RECRUITING · Early Phase 1
-
Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.